Fig. 5.
T-cell responses against influenza matrix protein epitope 56-64 in AML patients and healthy subjects.
Unstimulated PBMCs were analyzed for the recognition of influenza matrix protein 58-66 peptide by IFN-γ ELISPOT assay in 14 HLA-A2+ AML patients and 15 HLA-A2+ healthy subjects. Values are expressed as number of spots per 106 PBMC (white bars number of spots in unstimulated PBMCs; black/striped bars number of spots in response to peptide). Responses, which exceeded the number of spots in unstimulated PBMCs by 2-fold or more and had a minimum of 10 peptide-specific spots in 106 PBMCs (after subtracting the number of spots in unstimulated PBMCs) were considered peptide specific and are shown as striped bars.